C
Christopher D. Hart
Researcher at St. Vincent's Health System
Publications - 17
Citations - 567
Christopher D. Hart is an academic researcher from St. Vincent's Health System. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 8, co-authored 16 publications receiving 413 citations. Previous affiliations of Christopher D. Hart include Academy for Urban School Leadership.
Papers
More filters
Journal ArticleDOI
Quality indicators in breast cancer care: An update from the EUSOMA working group.
Laura Biganzoli,Lorenza Marotti,Christopher D. Hart,Luigi Cataliotti,B. Cutuli,Thorsten Kühn,Robert E. Mansel,Antonio Ponti,Philip Poortmans,Peter Regitnig,Jos A. van der Hage,Yvonne Wengström,Marco Rosselli Del Turco +12 more
TL;DR: If centres fail to meet the minimum standard, older patients will be excluded from analysis, provided that reasons for non-adherence to the QI are specified in the clinical chart and are identified at the review of the clinical records.
Journal ArticleDOI
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.
Christopher D. Hart,Ilenia Migliaccio,Luca Malorni,Cristina Guarducci,Laura Biganzoli,Angelo Di Leo +5 more
TL;DR: The current evidence that can guide treatment decisions in patients with advanced-stage ER+ breast cancer is examined, how to tackle these therapeutic challenges are discussed and suggestions for the optimal management of this patient population are provided.
Journal ArticleDOI
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
Luca Malorni,Silvano Piazza,Silvano Piazza,Yari Ciani,Cristina Guarducci,Martina Bonechi,Chiara Biagioni,Christopher D. Hart,Roberto Verardo,Angelo Di Leo,Ilenia Migliaccio +10 more
TL;DR: It is hypothesized that complex alterations of the Retinoblastoma (Rb) pathway might be implicated in resistance to CDK4/6 inhibitors and investigated whether signatures of Rb loss-of-function would identify breast cancer cell lines resistant to palbociclib.
Journal ArticleDOI
Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population
Christopher D. Hart,Alessia Vignoli,Leonardo Tenori,Gemma Leonora Uy,Ta Van To,Clement Adebamowo,Syed Mozammel Hossain,Laura Biganzoli,Emanuela Risi,Richard R. Love,Claudio Luchinat,Angelo Di Leo +11 more
TL;DR: In a multicenter group of EBC patients, a model based on preoperative serum metabolomic profiles was developed that was prognostic for disease recurrence, independent of traditional clinicopathologic risk factors.
Book ChapterDOI
Metabolomics in Breast Cancer: Current Status and Perspectives.
TL;DR: This chapter will review current metabolomic research in breast cancer, with a focus on efforts to translate the technology into clinical practice.